Evolus Total Liabilities 2016-2024 | EOLS

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Evolus total liabilities from 2016 to 2024. Total liabilities can be defined as the total value of all possible claims against the corporation.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Evolus total liabilities from 2016 to 2024. Total liabilities can be defined as the total value of all possible claims against the corporation.

Related Stocks
Company Name	Market Cap
Abbott Laboratories (ABT)	$203.2B
Stryker (SYK)	$148.2B
Boston Scientific (BSX)	$133.1B
EssilorLuxottica (ESLOY)	$113.5B
Medtronic (MDT)	$109B
Haleon (HLN)	$42.9B
Lonza Group Ag (LZAGY)	$42.1B
GE HealthCare Technologies (GEHC)	$37.7B
ResMed (RMD)	$35B
Terumo (TRUMY)	$29.2B
Koninklijke Philips (PHG)	$24.4B
Zimmer Biomet Holdings (ZBH)	$22.1B
Insulet (PODD)	$18.4B
Baxter (BAX)	$16.6B
Smith & Nephew SNATS (SNN)	$11.2B
BellRing Brands (BRBR)	$9.5B
Bio-Rad Laboratories (BIO)	$9B
Demant (WILYY)	$8.3B
Lantheus Holdings (LNTH)	$5.5B
TG Therapeutics (TGTX)	$4.7B
Haemonetics (HAE)	$4.3B
ICU Medical (ICUI)	$4.2B
Prestige Consumer Healthcare (PBH)	$4.1B
Perrigo (PRGO)	$3.7B
Envista Holdings (NVST)	$3.5B
Neogen (NEOG)	$3.3B
Agios Pharmaceuticals (AGIO)	$3.1B
Shandong Weigao Medical Polymer (SHWGF)	$3B
GN Store Nord (GNNDY)	$2.8B
QuidelOrtho (QDEL)	$2.6B